Jefferies analyst David Steinberg raised his price target for Collegium Pharmaceutical to $36 from $26 and keeps a Buy rating on the shares. The only item that really mattered from the Q3 earnings call is that Collegium contracted for 35M-plus additional lives on exclusive Xtampza contracts, Steinberg tells investors in a research note. Importantly, the company did not offer additional discounts to obtain them, adds the analyst. The earnings impact is "large," says Steinberg, who nearly doubled his 2021 earnings per share estimate from $1.26 to $2.40. He believes Collegium shares look "unusually inexpensive" and keeps a Buy rating on the name.